"The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is adminis"...
(Generic versions may still be available.)
Velosulin (insulin human) ® BR is a clear solution of insulin in a phosphate buffer. The concentration of this product is 100 units of insulin per milliliter. This human insulin is structurally identical to the insulin produced by the pancreas in the human body. This structural identity is obtained by recombinant-DNA technology utilizing Saccharomyces cerevisiae (bakers' yeast) as the production organism. When a U-100 insulin syringe is used to deliver the insulin, the effect of Velosulin (insulin human) ® BR begins approximately ½ hour after the injection. The effect lasts up to approximately 8 hours with a maximal effect between the 1 st and 3 rd hour.
The time course of action of any insulin may vary considerably in different individuals, or at different times in the same individual, or when using an external insulin infusion pump to deliver the insulin. Because of this variation, the time periods listed here should be considered as general guidelines only when using U-100 insulin syringes to deliver the insulin.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Velosulin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find tips and advances in treatment.